Cover Image
市場調查報告書

肝轉移的開發中產品分析

Hepatic (Liver) Metastasis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 255956
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
肝轉移的開發中產品分析 Hepatic (Liver) Metastasis - Pipeline Review, H2 2015
出版日期: 2015年10月21日 內容資訊: 英文 68 Pages
簡介

由於肝臟同時接受冠狀動脈及肝門靜脈雙重大量的血液供給,而成為了轉移性疾病的共通部位。其發病率也高達原發部位的20倍。由類洞的血液供給入侵的腫瘤栓塞雖然比庫氏細胞看起來更能物理性隔離,但要是朣瘤栓塞更大,就有傾向留在門脈的支流中。由於一般都會同時影響二個肝葉,幾乎無論是哪種疾病都沒有效果性治療法,外科切除也是不可能狀態。

本報告提供全球各國治療肝轉移的開發中產品開發狀況分析,提供開發中產品的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

肝轉移概要

治療藥的開發

  • 肝轉移用開發中產品:概要
  • 肝轉移用開發中產品:比較分析

各企業開發中的肝轉移治療藥

大學/研究機關研究中的肝轉移治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

肝轉移治療藥:開發中的產品一覽(各企業)

肝轉移治療藥:研究中的產品一覽(大學/研究機關別)

參與肝轉移治療藥開發的企業

  • Novartis AG
  • Cleveland BioLabs, Inc.
  • CytRx Corporation
  • S.L.A. Pharma AG
  • Incuron, LLC
  • Gradalis Inc.
  • TARGETOME

肝轉移:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • icosapent
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • FANG疫苗
  • 177Lu-DOTA-TATE
  • pasireotide
  • entolimod
  • Curcumin C3-Complex + fluorouracil + oxaliplatin + leucovorin calcium
  • mepacrine
  • disulfiram + copper gluconate
  • Salmonella typhimurium
  • Anti-CEA Designer T Cells
  • Antibody Against FERM Domain-Containing Protein 4A
  • Cyt-HiPoA
  • TGM-001
  • TGM-002
  • TGM-003
  • Fv-p53
  • TGM-004
  • TGM-005

肝轉移治療藥:最新的藥物簡介

肝轉移治療藥:開發暫停的產品

肝轉移相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿(1件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7249IDB

Summary

Global Markets Direct's, 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2015', provides an overview of the Hepatic (Liver) Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Metastasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hepatic (Liver) Metastasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Metastasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Metastasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatic (Liver) Metastasis Overview
  • Therapeutics Development
    • Pipeline Products for Hepatic (Liver) Metastasis - Overview
    • Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis
  • Hepatic (Liver) Metastasis - Therapeutics under Development by Companies
  • Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes
  • Hepatic (Liver) Metastasis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hepatic (Liver) Metastasis - Products under Development by Companies
  • Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes
  • Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • BioCancell Ltd
    • CytRx Corporation
    • Digna Biotech, S.L.
    • Gradalis Inc.
    • Incuron, LLC
    • Novartis AG
    • Phosplatin Therapeutics LLC
    • Targetome
  • Hepatic (Liver) Metastasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies to Inhibit FRMD4A for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-821 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cancer vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target CEA for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyt-HiPoA - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DB-02901 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mepacrine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MS-417 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PT-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • talimogene laherparepvec - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGM-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGM-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hepatic (Liver) Metastasis - Recent Pipeline Updates
  • Hepatic (Liver) Metastasis - Dormant Projects
  • Hepatic (Liver) Metastasis - Discontinued Products
  • Hepatic (Liver) Metastasis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 16, 2014: Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hepatic (Liver) Metastasis, H2 2015
  • Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Amgen Inc., H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by BioCancell Ltd, H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Digna Biotech, S.L., H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Phosplatin Therapeutics LLC, H2 2015
  • Hepatic (Liver) Metastasis - Pipeline by Targetome, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Hepatic (Liver) Metastasis - Dormant Projects, H2 2015
  • Hepatic (Liver) Metastasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Hepatic (Liver) Metastasis, H2 2015
  • Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top